# Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes

> **NCT03556098** · NA · COMPLETED · sponsor: **Steno Diabetes Center Copenhagen** · enrollment: 12 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** glucose-dependent insulinotropic peptide
- **DRUG:** Glucose-Dependent Insulin-Releasing Hormone[3-30]
- **DRUG:** Saline Solution

## Key facts

- **NCT ID:** NCT03556098
- **Lead sponsor:** Steno Diabetes Center Copenhagen
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-22
- **Primary completion:** 2020-02-11
- **Final completion:** 2020-02-11
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03556098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03556098, "Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03556098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*